The EmDia trial, designed to study the effects of the sodium glucose cotransporter‐2 (SGLT2) inhibitor empagliflozin on cardiovascular comorbidities in type 2 diabetes mellitus (T2DM) patients, has been investigated for short‐term metabolic alterations by a limited set of clinical assays. The gene discussed is SLC5A2; the disease is diabetes mellitus.